£122bn
in healthcare costs
result from brain
disorders such as dementia and stroke
By creating the Clinical Innovation
Zone and ability for industry to co-
locate with us, we invite big and
small companies to come to Glasgow
to create new jobs and to interact
with our scientists. This way the
whole enterprise becomes much more
valuable because there is economic
growth for the city.
How does the project contribute
to industry collaboration?
This Clinical Innovation Zone brings
together companies that add value to
the innovation ecosystem. There will
be DNA sequencing and advanced
bioinformatics combined with imaging,
joining together to create unique
capabilities in precision medicine
with access to electronic health
records across Scotland.
Industry partners Thermo Fisher
Scientific, an international diagnostics
company, and Aridhia Informatics, a
local small-medium enterprise (SME),
work with us currently, but we also
have space for other SMEs that fit
strategically into precision medicine
as a big theme. The Clinical Innovation
Zone will bring companies that add
value together to collaborate, create
jobs and improve the Scottish
economy. I also think the 7-Tesla
will be a magnet for big research
grants, as well as for industry
engagement and collaboration. ■
For further information on
infrastructure, approaches, and
collaboration please contact: Dr Carol
Clugston, Chief Operating Officer
[email protected]
R e a d o n l i n e at: u k s pa . o r g . u k / b r e a k t h r o u g h
Professor Dame Anna Dominiczak
Vice Principal at the University of Glasgow
Professor Dame Anna Dominiczak DBE,
FRCP, FRSE, FAHA, FMedSci is head of the
College of Medical, Veterinary and Life Sciences
(MVLS) and Regius Chair of Medicine
S U M M E R 2 0 17 | U K S PA b r e akt h r o u g h | 41